Prenatal Chagas disease screening in Latin America: the current policy landscape and potential utility of an expanded maternal-familial <i>Trypanosoma cruzi</i> testing framework.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40502726.
- Also identified by DOI 10.1016/j.lana.2025.101139 and PMC identifier 12158603.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 2018, revised World Health Organization guidance moved toward eliminating congenital Chagas disease (<i>Trypanosoma cruzi</i>)-a traditionally vector-borne parasitic disease that can chronically infect persons and be vertically transmitted from untreated mothers to their fetuses during pregnancy. Several endemic countries have since adopted risk-based or universal prenatal screening policies with high variation among strategies, implementation, coverage, and reporting. This article describes a collaborative investigation between researchers and the Salvadoran Ministry of Health, where expanded infant and family follow-up testing was executed after mothers tested <i>T. cruzi</i> positive during parturition. In this pilot study, we found 16% (n = 5/32) of familial members tested positive for previously undiagnosed infection. This manuscript highlights lessons learned from a familial follow-up testing initiative, provides rationale in support of expanding the maternal-familial <i>T. cruzi</i> screening framework in endemic countries, and describes updates on international progress towards implementation of prenatal screening as indicated by updated World Health Organization guidance.